vs
ASTROTECH Corp（ASTC）与CytoMed Therapeutics Ltd（GDTC）财务数据对比。点击上方公司名可切换其他公司
ASTROTECH Corp的季度营收约是CytoMed Therapeutics Ltd的1.3倍（$148.0K vs $115.4K），CytoMed Therapeutics Ltd自由现金流更多（$-855.4K vs $-4.0M）
航天科技公司（原名Spacehab Inc.）是一家总部位于美国得克萨斯州奥斯汀的科技孵化企业。该公司整合内部、研究机构、政府实验室及高校的技术资源，投资、孵化并退出初创企业，旗下子公司还为美国航空航天局、美国国防部、各国航天机构及全球商业客户提供商业化产品与服务。
CytoMed Therapeutics是一家临床阶段生物制药企业，专注于开发同种异体CAR-T细胞疗法，用于治疗血液恶性肿瘤与实体瘤，深耕肿瘤免疫领域，致力于满足全球癌症患者未被满足的临床治疗需求。
ASTC vs GDTC — 直观对比
营收规模更大
ASTC
是对方的1.3倍
$115.4K
自由现金流更多
GDTC
多$3.1M
$-4.0M
损益表 — Q2 FY2026 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $148.0K | $115.4K |
| 净利润 | $-3.9M | — |
| 毛利率 | 5.4% | — |
| 营业利润率 | -2635.8% | — |
| 净利率 | -2653.4% | — |
| 营收同比 | -43.3% | — |
| 净利润同比 | 2.0% | — |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTCGDTC
| Q4 25 | $148.0K | — | ||
| Q3 25 | $297.0K | — | ||
| Q2 25 | $220.0K | $115.4K | ||
| Q1 25 | $534.0K | — | ||
| Q4 24 | $261.0K | — | ||
| Q4 23 | $1.1M | — | ||
| Q3 23 | $425.0K | — | ||
| Q2 23 | $414.0K | — |
净利润ASTCGDTC
| Q4 25 | $-3.9M | — | ||
| Q3 25 | $-3.5M | — | ||
| Q2 25 | $-2.9M | — | ||
| Q1 25 | $-3.6M | — | ||
| Q4 24 | $-4.0M | — | ||
| Q4 23 | $-2.6M | — | ||
| Q3 23 | $-2.9M | — | ||
| Q2 23 | $-2.3M | — |
毛利率ASTCGDTC
| Q4 25 | 5.4% | — | ||
| Q3 25 | 63.3% | — | ||
| Q2 25 | 33.6% | — | ||
| Q1 25 | 44.4% | — | ||
| Q4 24 | 59.4% | — | ||
| Q4 23 | 47.7% | — | ||
| Q3 23 | 43.1% | — | ||
| Q2 23 | 43.7% | — |
营业利润率ASTCGDTC
| Q4 25 | -2635.8% | — | ||
| Q3 25 | -1190.6% | — | ||
| Q2 25 | -1326.4% | — | ||
| Q1 25 | -724.2% | — | ||
| Q4 24 | -1655.6% | — | ||
| Q4 23 | -275.2% | — | ||
| Q3 23 | -784.7% | — | ||
| Q2 23 | -659.7% | — |
净利率ASTCGDTC
| Q4 25 | -2653.4% | — | ||
| Q3 25 | -1166.7% | — | ||
| Q2 25 | -1331.8% | — | ||
| Q1 25 | -680.3% | — | ||
| Q4 24 | -1536.0% | — | ||
| Q4 23 | -236.9% | — | ||
| Q3 23 | -685.2% | — | ||
| Q2 23 | -560.4% | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.0M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $15.5M | — |
| 总资产 | $19.7M | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASTCGDTC
| Q4 25 | $7.0M | — | ||
| Q3 25 | $11.3M | — | ||
| Q2 25 | $15.1M | — | ||
| Q1 25 | $18.1M | — | ||
| Q4 24 | $21.5M | — | ||
| Q4 23 | $52.4M | — | ||
| Q3 23 | $51.7M | — | ||
| Q2 23 | $55.8M | — |
股东权益ASTCGDTC
| Q4 25 | $15.5M | — | ||
| Q3 25 | $19.1M | — | ||
| Q2 25 | $22.1M | — | ||
| Q1 25 | $24.8M | — | ||
| Q4 24 | $28.1M | — | ||
| Q4 23 | $40.3M | — | ||
| Q3 23 | $42.1M | — | ||
| Q2 23 | $44.7M | — |
总资产ASTCGDTC
| Q4 25 | $19.7M | — | ||
| Q3 25 | $23.2M | — | ||
| Q2 25 | $27.0M | — | ||
| Q1 25 | $27.5M | — | ||
| Q4 24 | $31.0M | — | ||
| Q4 23 | $42.8M | — | ||
| Q3 23 | $44.6M | — | ||
| Q2 23 | $47.7M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.5M | $-855.3K |
| 自由现金流经营现金流 - 资本支出 | $-4.0M | $-855.4K |
| 自由现金流率自由现金流/营收 | -2671.6% | -741.5% |
| 资本支出强度资本支出/营收 | 277.7% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-14.9M | — |
8季度趋势，按日历期对齐
经营现金流ASTCGDTC
| Q4 25 | $-3.5M | — | ||
| Q3 25 | $-3.9M | — | ||
| Q2 25 | $-2.4M | $-855.3K | ||
| Q1 25 | $-3.9M | — | ||
| Q4 24 | $-3.0M | — | ||
| Q4 23 | $-1.8M | — | ||
| Q3 23 | $-3.0M | — | ||
| Q2 23 | $-1.3M | — |
自由现金流ASTCGDTC
| Q4 25 | $-4.0M | — | ||
| Q3 25 | $-4.4M | — | ||
| Q2 25 | $-2.7M | $-855.4K | ||
| Q1 25 | $-3.9M | — | ||
| Q4 24 | $-3.4M | — | ||
| Q4 23 | $-2.0M | — | ||
| Q3 23 | $-3.1M | — | ||
| Q2 23 | $-1.8M | — |
自由现金流率ASTCGDTC
| Q4 25 | -2671.6% | — | ||
| Q3 25 | -1476.1% | — | ||
| Q2 25 | -1231.4% | -741.5% | ||
| Q1 25 | -728.1% | — | ||
| Q4 24 | -1288.5% | — | ||
| Q4 23 | -175.2% | — | ||
| Q3 23 | -723.3% | — | ||
| Q2 23 | -437.2% | — |
资本支出强度ASTCGDTC
| Q4 25 | 277.7% | — | ||
| Q3 25 | 150.8% | — | ||
| Q2 25 | 158.2% | 0.0% | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 122.2% | — | ||
| Q4 23 | 13.7% | — | ||
| Q3 23 | 5.6% | — | ||
| Q2 23 | 126.8% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
